Due to the success of modern antiretroviral therapy (ART) and an increase in the average age of new HIV diagnoses, the population of Canadians living with HIV is aging. Aging in itself is a complex and poorly understood process, which is experienced differently among people. As with any chronic condition, the interaction between HIV and aging increases this complexity and presents a unique set of challenges.
The UN has expanded the response to the global HIV epidemic to include the elimination of viral hepatitis and other sexually transmitted and blood-borne infections (STBBIs), such as syphilis and gonorrhea. Over the history of the CTN, our investigators have contributed impactful research focused on STBBIs.
Within the CTN, the Vaccines and Immunotherapies (VIT) Research Core, led by Drs. Mario Ostrowski and Jean-Pierre Routy, focuses on research in targeted immunotherapies, prophylactic and therapeutic vaccines, and emerging areas of research in treatment and immune system support.
Dr. Jean-Pierre Routy
Guidelines for patient care help to support the use of best practices by clinicians, community members, and policy makers.
Community engagement (including the greater involvement and meaningful engagement of people living with HIV [GIPA/MEPA]) are core values of the CTN. These values coincide with CIHR’s policy for citizen engagement in all of its funding programs, including its HIV and CTN-funded research.
